Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma

2016 ◽  
Vol 58 ◽  
pp. 112-121 ◽  
Author(s):  
Michael A. Fridrik ◽  
Ulrich Jaeger ◽  
Andreas Petzer ◽  
Wolfgang Willenbacher ◽  
Felix Keil ◽  
...  
Keyword(s):  
B Cell ◽  
Liposomal Doxorubicin ◽  
Cell Lymphoma ◽  
Pegylated Liposomal Doxorubicin ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Frontline Treatment ◽  
Large B Cell

scholarly journals Aggressive chemotherapy in frail patients with diffuse large B-cell lymphoma: The role of pegylated liposomal doxorubicin

2012 ◽  
Vol 2 (2) ◽  
Author(s):  
Natividad Neri ◽  
Agustin Avilés ◽  
Christian Johannes Schmitt ◽  
Marielle Scherrer-Crosbie ◽  
Lesley A Smith ◽  
...  
Keyword(s):  
B Cell ◽  
Liposomal Doxorubicin ◽  
Cell Lymphoma ◽  
Pegylated Liposomal Doxorubicin ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Frail Patients ◽  
Large B Cell

Pegylated Liposomal Doxorubicin in Combination Chemotherapy in the Treatment of Previously Untreated Aggressive Diffuse Large-B-Cell Lymphoma

2002 ◽  
Vol 19 (1) ◽  
pp. 55-58 ◽  
Author(s):  
Agustin Avilés ◽  
Natividad Neri ◽  
Claudia Castañeda ◽  
Alejandra Talavera ◽  
Judith Huerta-Guzmán ◽  
...  
Keyword(s):  
B Cell ◽  
Combination Chemotherapy ◽  
Liposomal Doxorubicin ◽  
Cell Lymphoma ◽  
Pegylated Liposomal Doxorubicin ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 1933 ◽  
Author(s):  
Jung Yong Hong ◽  
Cheolwon Suh ◽  
Won Seog Kim
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Targeted Agents ◽  
Cell Of Origin ◽  
Cell Subtype ◽  
Large B Cell Lymphoma ◽  
Frontline Treatment ◽  
Double Hit ◽  
Large B Cell

Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.

Sign in / Sign up

Export Citation Format

Share Document